Guidant Has All Its Eggs In Paclitaxel-Coated Basket...For Now

Guidant's decision to halt its in-house actinomycin-D drug-eluting stent program raises the stakes of an upcoming court ruling on whether Cook violated a 1997 co-exclusive agreement between Angiotech Pharmaceuticals and Boston Scientific